EU regulator advises use of Regeneron antibody cocktail for COVID-19
Europe’s medicines regulator said on Friday an antibody drug combination developed by Regeneron Pharmaceuticals can be used to treat COVID-19 patients who do not require oxygen support and are at high risk of progressing to severe illness. The recommendation can now be used as guidance in individual European nations on the possible use of the combination of casirivimab and imdevimab before a marketing authorisation is issued, the European Medicines Agency (EMA) said. Regeneron’s antibody cocktail was authorised for emergency use in the United States in November, and was given to former U.S. President Donald Trump during his COVID-19 infection. The treatment, given via a drip, is part of a class of drugs known as monoclonal antibodies, which are manufactured copies of antibodies created by the human body to fight infections.
Reuters - February 26, 2021View the full story here: https://www.reuters.com/article/us-health-coronavirus-europe-antibody/eu-regulator-advises-use-of-regeneron-antibody-cocktail-for-covid-19-idUSKBN2AQ1KD?il=0